At the news
? NEUTRALIMPACT 4/10 8-K filed Jul 13, 2026 at 09:03 ET
Oncolytics Biotech provided a clinical and regulatory update on its REO 033 study in RAS-mutant MSS colorectal cancer, reporting that half of planned clinical sites will be activated by end of July with over 20 patients pre-identified. The company will hold a Type D meeting with the FDA in early August 2026 to discuss adding a registrational Part B to the study, which could support accelerated and full approval. Initial tumor response data from Part A is expected by year-end 2026, with Part B enrollment potentially starting Q1 2027.
- Half of planned clinical sites for REO 033 will be activated by end of July 2026; over 20 patients pre-identified across centers.
- Type D meeting with FDA scheduled for first half of August 2026 to discuss registrational expansion via Part B of REO 033.
- Part B designed as a randomized study with blinded independent central review to support potential accelerated and full approval.
- Initial tumor response update from Part A expected by year-end 2026; Part B enrollment targeted for Q1 2027 subject to FDA feedback.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access